Primary Antibodies

Tislelizumab (anti-PDCD1), a monoclonal antibody with high binding affinity to the PD-1 receptor, minimizes Fcγ receptor binding on macrophages, thereby abrogating antibody-dependent phagocytosis, a mechanism of T cell clearance and potential

Tislelizumab (anti-PDCD1), a monoclonal antibody with high binding affinity to the PD-1 receptor, minimizes Fcγ receptor binding on macrophages, thereby abrogating antibody-dependent phagocytosis, a mechanism of T cell clearance and potential

Tislelizumab (anti-PDCD1), a monoclonal antibody with high binding affinity to the PD-1 receptor, minimizes Fcγ receptor binding on macrophages, thereby abrogating antibody-dependent phagocytosis, a mechanism of T cell clearance and potential

Mouse anti Human VAV1 Antibody, Monoclonal (1582CT802.383.58), could be used for WB and so on.Application· WB: 1/4000 Protein FunctionCouples tyrosine kinase signals with the activation of the Rho/Rac GTPases, thus leading to cell differentiation

Mouse anti Human VAV1 Antibody, Monoclonal (1582CT802.383.58), could be used for WB and so on.Application· WB: 1/4000 Protein FunctionCouples tyrosine kinase signals with the activation of the Rho/Rac GTPases, thus leading to cell differentiation

Mouse anti Human VAV1 Antibody, Monoclonal (1582CT802.383.58), could be used for WB and so on.Application· WB: 1/4000 Protein FunctionCouples tyrosine kinase signals with the activation of the Rho/Rac GTPases, thus leading to cell differentiation

Mouse anti Human VAV1 Antibody, Monoclonal (1582CT802.383.58), could be used for WB and so on.Application· WB: 1/4000 Protein FunctionCouples tyrosine kinase signals with the activation of the Rho/Rac GTPases, thus leading to cell differentiation

Xentuzumab (anti-IGF1) is a recombinant a humanized monoclonal antibody that targets IGF ligands IGF1 and IGF2. Xentuzumab (anti-IGF1) inhibits both of IGF1 and IGF2 growth-promoting signalling and suppresses AKT activation.Purity&gt95%

Xentuzumab (anti-IGF1) is a recombinant a humanized monoclonal antibody that targets IGF ligands IGF1 and IGF2. Xentuzumab (anti-IGF1) inhibits both of IGF1 and IGF2 growth-promoting signalling and suppresses AKT activation.Purity&gt95%

Xentuzumab (anti-IGF1) is a recombinant a humanized monoclonal antibody that targets IGF ligands IGF1 and IGF2. Xentuzumab (anti-IGF1) inhibits both of IGF1 and IGF2 growth-promoting signalling and suppresses AKT activation.Purity&gt95%

Xentuzumab (anti-IGF1) is a recombinant a humanized monoclonal antibody that targets IGF ligands IGF1 and IGF2. Xentuzumab (anti-IGF1) inhibits both of IGF1 and IGF2 growth-promoting signalling and suppresses AKT activation.Purity&gt95%